No Data
Express News | Gilead to Invest $32 Billion in U.S. Manufacturing and R&D Through 2030 and Create More Than 3,000 Direct and Indirect Jobs by 2028
Gilead Sciences (NasdaqGS:GILD) Presents Promising Data On Livdelzi And Bulevirtide At EASL 2025
Express News | Gilead Showcases Livdelzi's Efficacy And Tolerability In PBC, With 60% Response Rate Among Patients With Prior Fibrate Or OCA Use, At EASL 2025
Express News | Gilead's Bulevirtide Shows Durability In Chronic HDV, With 90% of Patients on Long-Term Therapy Maintaining Undetectable HDV RNA Off-Treatment
Trump wants to impose tariffs on Pharmaceuticals: Pharmaceutical companies are busy stockpiling, and the import volume in the USA surged in March.
① The volume of Pharmaceutical imports in the USA surged in March, as pharmaceutical companies stockpiled products in anticipation of potential tariffs; ② A report released by the US Department of Commerce on Tuesday showed that the total value of Pharmaceutical imports in March exceeded 50 billion USD, equivalent to 20% of the total Pharmaceutical imports for the entire year of 2024.
Moderna, Pharma Stocks Fall as FDA Names Industry Critic as Top Vaccine Regulator
小粉红的papa : It seems that not many people pay attention to biopharmaceutical Stocks, it's quite niche.
Everyone only invests in Technology Stocks.